{"name": "Gemin X Pharmaceuticals",
 "permalink": "gemin-x-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/gemin-x-pharmaceuticals",
 "homepage_url": "http://www.geminx.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1998,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@geminx.com",
 "phone_number": "514-281-8989",
 "description": "",
 "created_at": "Thu Mar 11 09:18:21 UTC 2010",
 "updated_at": "Tue Mar 22 07:45:52 UTC 2011",
 "overview": "\u003Cp\u003EGemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.\u003C/p\u003E\n\n\u003Cp\u003EGemin X\u0026#8217;s research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       41],
      "assets/images/resized/0007/9935/79935v1-max-150x150.jpg"],
     [[250,
       68],
      "assets/images/resized/0007/9935/79935v1-max-250x250.jpg"],
     [[263,
       72],
      "assets/images/resized/0007/9935/79935v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman and Chief Executive Officer",
    "person":
     {"first_name": "Peter",
      "last_name": "R. Dolan",
      "permalink": "peter-r-dolan",
      "image": null}},
   {"is_past": false,
    "title": "Executive Vice President and Chief Medical Officer",
    "person":
     {"first_name": "Jean",
      "last_name": "Viallet",
      "permalink": "jean-viallet",
      "image": null}},
   {"is_past": false,
    "title": "Chief Scientific Officer and Co-founder",
    "person":
     {"first_name": "Gordon",
      "last_name": "C. Shore",
      "permalink": "gordon-c-shore",
      "image": null}},
   {"is_past": false,
    "title": "Chief Financial Officer",
    "person":
     {"first_name": "Michael",
      "last_name": "Dixon",
      "permalink": "michael-dixon-2",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$62M",
 "funding_rounds":
  [{"round_code": "c",
    "source_url": "http://www.siliconindia.com/shownews/Gemin_X_Pharmaceuticals_closes_38_Mn_Series_C_financing-nid-43319.html",
    "source_description": "Gemin X Pharmaceuticals closes $38 Mn Series C financing",
    "raised_amount": 38000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 7,
    "funded_day": 3,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Caxton Advantage Life Sciences Fund",
         "permalink": "caxton-advantage-life-sciences-fund",
         "image":
          {"available_sizes":
            [[[150,
               9],
              "assets/images/resized/0025/6631/256631v1-max-150x150.png"],
             [[250,
               15],
              "assets/images/resized/0025/6631/256631v1-max-250x250.png"],
             [[450,
               27],
              "assets/images/resized/0025/6631/256631v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "H.I.G. Ventures",
         "permalink": "h-i-g-ventures",
         "image":
          {"available_sizes":
            [[[150,
               67],
              "assets/images/resized/0010/2205/102205v1-max-150x150.jpg"],
             [[206,
               93],
              "assets/images/resized/0010/2205/102205v1-max-250x250.jpg"],
             [[206,
               93],
              "assets/images/resized/0010/2205/102205v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "VantagePoint Capital Partners",
         "permalink": "vantagepoint-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               38],
              "assets/images/resized/0001/0782/10782v3-max-150x150.png"],
             [[250,
               64],
              "assets/images/resized/0001/0782/10782v3-max-250x250.png"],
             [[254,
               66],
              "assets/images/resized/0001/0782/10782v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "ProQuest Investments",
         "permalink": "proquest-investments",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0005/2876/52876v1-max-150x150.jpg"],
             [[236,
               79],
              "assets/images/resized/0005/2876/52876v1-max-250x250.jpg"],
             [[236,
               79],
              "assets/images/resized/0005/2876/52876v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Merlin Biomed",
         "permalink": "merlin-biomed",
         "image":
          {"available_sizes":
            [[[150,
               63],
              "assets/images/resized/0006/8420/68420v2-max-150x150.jpg"],
             [[244,
               104],
              "assets/images/resized/0006/8420/68420v2-max-250x250.jpg"],
             [[244,
               104],
              "assets/images/resized/0006/8420/68420v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HBM Partners",
         "permalink": "hbm-partners",
         "image":
          {"available_sizes":
            [[[150,
               48],
              "assets/images/resized/0007/9948/79948v1-max-150x150.jpg"],
             [[190,
               62],
              "assets/images/resized/0007/9948/79948v1-max-250x250.jpg"],
             [[190,
               62],
              "assets/images/resized/0007/9948/79948v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Canadian Medical Discoveries Fund",
         "permalink": "canadian-medical-discoveries-fund",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ontario Teachers Pension Plan",
         "permalink": "ontario-teachers-pension-plan",
         "image":
          {"available_sizes":
            [[[150,
               62],
              "assets/images/resized/0006/0997/60997v1-max-150x150.png"],
             [[174,
               72],
              "assets/images/resized/0006/0997/60997v1-max-250x250.png"],
             [[174,
               72],
              "assets/images/resized/0006/0997/60997v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "SB Life Science",
         "permalink": "sb-life-science",
         "image":
          {"available_sizes":
            [[[87,
               98],
              "assets/images/resized/0007/9949/79949v1-max-150x150.jpg"],
             [[87,
               98],
              "assets/images/resized/0007/9949/79949v1-max-250x250.jpg"],
             [[87,
               98],
              "assets/images/resized/0007/9949/79949v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Business Development Bank of Canada",
         "permalink": "business-development-bank-of-canada",
         "image":
          {"available_sizes":
            [[[150,
               63],
              "assets/images/resized/0004/9870/49870v2-max-150x150.png"],
             [[211,
               89],
              "assets/images/resized/0004/9870/49870v2-max-250x250.png"],
             [[211,
               89],
              "assets/images/resized/0004/9870/49870v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Solidarity Fund QFL",
         "permalink": "solidarity-fund-qfl",
         "image":
          {"available_sizes":
            [[[150,
               77],
              "assets/images/resized/0003/2081/32081v1-max-150x150.png"],
             [[177,
               91],
              "assets/images/resized/0003/2081/32081v1-max-250x250.png"],
             [[177,
               91],
              "assets/images/resized/0003/2081/32081v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Pinnacle Ventures",
         "permalink": "pinnacle-ventures",
         "image":
          {"available_sizes":
            [[[150,
               62],
              "assets/images/resized/0001/0788/10788v1-max-150x150.png"],
             [[226,
               94],
              "assets/images/resized/0001/0788/10788v1-max-250x250.png"],
             [[226,
               94],
              "assets/images/resized/0001/0788/10788v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "d",
    "source_url": "http://www.fiercebiotech.com/story/gemin-x-books-16m-series-d-it-pursues-phiib-cancer-trial/2010-04-20",
    "source_description": "Gemin X books $16M Series D as it pursues PhIIb cancer trial  Read more: http://www.fiercebiotech.com/story/gemin-x-books-16m-series-d-it-pursues-phiib-cancer-trial/2010-04-20#ixzz0lfnwA8xR",
    "raised_amount": 16000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 4,
    "funded_day": 20,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Caxton Advantage Life Sciences Fund",
         "permalink": "caxton-advantage-life-sciences-fund",
         "image":
          {"available_sizes":
            [[[150,
               9],
              "assets/images/resized/0025/6631/256631v1-max-150x150.png"],
             [[250,
               15],
              "assets/images/resized/0025/6631/256631v1-max-250x250.png"],
             [[450,
               27],
              "assets/images/resized/0025/6631/256631v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "e",
    "source_url": "http://onbiovc.com/gemin-x-pharmaceuticals-inc-series-e-8m/",
    "source_description": "Gemin X Pharmaceuticals, Inc.: Series E $8M",
    "raised_amount": 8000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 8,
    "funded_day": 24,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Caxton Advantage Life Sciences Fund",
         "permalink": "caxton-advantage-life-sciences-fund",
         "image":
          {"available_sizes":
            [[[150,
               9],
              "assets/images/resized/0025/6631/256631v1-max-150x150.png"],
             [[250,
               15],
              "assets/images/resized/0025/6631/256631v1-max-250x250.png"],
             [[450,
               27],
              "assets/images/resized/0025/6631/256631v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sanderling Ventures",
         "permalink": "sanderling-ventures",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/4787/44787v2-max-150x150.jpg"],
             [[250,
               86],
              "assets/images/resized/0004/4787/44787v2-max-250x250.jpg"],
             [[304,
               105],
              "assets/images/resized/0004/4787/44787v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": 525000000.0,
   "price_currency_code": "USD",
   "term_code": "cash_and_stock",
   "source_url": "http://www.cephalon.com/media/news-releases.html?mode=year\u0026filterval=2011",
   "source_description": "Cephalon Announces Definitive Agreement to Acquire Gemin X",
   "acquired_year": 2011,
   "acquired_month": 3,
   "acquired_day": 21,
   "acquiring_company":
    {"name": "Cephalon",
     "permalink": "cephalon",
     "image":
      {"available_sizes":
        [[[150,
           46],
          "assets/images/resized/0007/7997/77997v1-max-150x150.jpg"],
         [[233,
           73],
          "assets/images/resized/0007/7997/77997v1-max-250x250.jpg"],
         [[233,
           73],
          "assets/images/resized/0007/7997/77997v1-max-450x450.jpg"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "3576 Avenue du Parc",
    "address2": "Suite 4310, QC",
    "zip_code": "H2X 2H7",
    "city": "Montreal",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        128],
       "assets/images/resized/0007/9936/79936v1-max-150x150.jpg"],
      [[250,
        213],
       "assets/images/resized/0007/9936/79936v1-max-250x250.jpg"],
      [[450,
        384],
       "assets/images/resized/0007/9936/79936v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}